Boosting Drug Delivery: Protein–Polymer Nanoparticles with Enhanced Load Capacity and Stability

In a significant advancement for drug delivery technologies, scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new class of protein–polymer nanoparticles that can carry greater drug payloads while offering improved long-term stability. Their findings, published in the journal ACS Applied Materials & Interfaces, promise to reshape how we treat diseases such as cancer by reducing side effects and increasing treatment efficiency.
This innovative approach combines PLGA (a widely used biodegradable polymer in medicine) with albumin (a natural blood protein that already plays a role in pharmaceutical formulations). When mixed, the two form stable, uniform nanoparticles that can carry an astonishing 40% by weight of the chemotherapy drug doxorubicin—a significant leap compared to existing drugs like Doxil, which typically contain around 11%.
Solving Longstanding Challenges
Current nanoparticle-based drug delivery systems face two main issues: low drug loading capacity and poor stability. Many systems tend to clump over time and degrade quickly, limiting their practical use. These newly developed nanoparticles overcome both hurdles simultaneously.
"We managed to solve two big problems at once," explains Dr. Gang Ruan, Senior Associate Professor at XJTLU. By using albumin—a protein that naturally helps transport molecules in the body—the nanoparticles achieve a biocompatible and stable structure that works harmoniously with PLGA to enhance drug delivery efficacy.
Innovative Drug Loading Techniques
The research team used a dual-loading strategy to incorporate drugs into the nanoparticles. The drug is introduced during particle formation and again afterward via passive diffusion. This two-step loading method ensures better retention and release control, critical for chronic diseases requiring sustained drug delivery.
Preclinical tests on cell cultures and animal models showed strong therapeutic performance with reduced toxicity to healthy tissues. Even after six months, the nanoparticles maintained their structure and effectiveness—a rare achievement in the world of nanomedicine.
Toward Scalable and Versatile Drug Delivery
The scalability of this approach is promising. The team successfully demonstrated that large-scale production is feasible without compromising the nanoparticles' quality. Moreover, they plan to adapt this platform to deliver various types of drugs, opening doors to customizable therapies for cancer and other chronic conditions.
This study underscores the powerful synergy between biology and polymer science and illustrates how hybrid materials can outperform traditional delivery methods. As the next step, researchers will likely explore clinical trials and further improvements in targeting capabilities.
For the full article, see: https://phys.org/news/2025-06-proteinpolymer-nanoparticles-higher-drug-stability.html
Sponsored by PWmat (Lonxun Quantum) – a leading developer of GPU-accelerated materials simulation software for cutting-edge quantum, energy, and semiconductor research. Learn more about our solutions at: https://www.pwmat.com/en
📘 Download our latest company brochure to explore our software features, capabilities, and success stories: PWmat PDF Brochure
📞 Phone: +86 400-618-6006
📧 Email: support@pwmat.com
Comments
Post a Comment